PDCD1 and neoplasm: There are monoclonal antibodies such as anti-CTLA4 [45] and anti-PD-1/PD-L1 [46] that impair negative regulators, or checkpoints, of the adaptive immune system, leading to significant antitumor activity—and even cures—in different tumor types [47].